Anti-Mouse CD96 – Purified in vivo PLATINUM™ Functional Grade
Anti-Mouse CD96 – Purified in vivo PLATINUM™ Functional Grade
Product No.: C780
Clone 3.3 Target CD96 Formats AvailableView All Product Type Monoclonal Antibody Alternate Names Tactile (T cell-activated increased late expression) Isotype Rat IgG1 κ Applications B , FC , in vivo |
Antibody DetailsProduct DetailsReactive Species Mouse Host Species Rat Recommended Isotype Controls Recommended Dilution Buffer Product Concentration ≥ 5.0 mg/ml Endotoxin Level <0.5 EU/mg as determined by the LAL method Purity ≥98% monomer by analytical SEC ⋅ >95% by SDS Page Formulation This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration. Product Preparation Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates. Pathogen Testing To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s Purified Functional PLATINUM™ antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile. Storage and Handling Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles. Country of Origin USA Shipping Next Day 2-8°C RRIDAB_2829606 Applications and Recommended Usage? Quality Tested by Leinco FC The suggested concentration for this clone 3.3 antibody (anti-mouse CD96) for staining cells in flow cytometry is ≤ 1.0 μg per 106 cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application. Additional Applications Reported In Literature ? B Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity Clone 3.3 recognizes an epitope on mouse CD96.
Background CD96 is a single pass type I transmembrane glycoprotein in the immunoglobulin superfamily that is heavily N-glycosylated1. Murine (m) CD96 is present at the surface of most lymphocytes, including NK, CD4+ T, CD8+ T, NKT, and γδ T cells, but not B lymphocytes, neutrophils, macrophages, or dendritic cells2. mCD96 interacts with mCD155 and nectin-1 (CD111)1. A V-like domain mediates binding of mCD96 to mCD155 via interaction between amino acids of the FG loop of one binding partner with residues in the C’C’’-loop of the other. CD96 is a member of an interaction network that includes adhesion, activation, and inhibition activities.
CD96 contains three Ig-like domains that are separated from the transmembrane domain by a long proline, serine, and threonine rich stalk that undergoes extensive O-linked glycomodification1. The stalk may play a role in orientation or presentation of the Ig-like domains. mAb 3.3 binds to the first Ig domain and competes with CD155 for binding3. Human CD96 has a mild boosting effect on 2B4- and NKp30-mediated killing, but a direct role in the activation of NK cell-mediated cytotoxicity in vitro has not been observed 1. In contrast, mCD96 suppresses NK cells in vivo>2. Blocking studies show that mCD96 competes with CD226 for CD155 binding and limits NK cell function by direct inhibition2. Additionally, blocking mCD96 in vivo with mAb 3.3 protects against metastasis in three different tumor models. The antimetastatic effect of mAb 3.3 is independent of antibody-dependent cell-mediated cytotoxicity and activating Fc receptors3,4 and is enhanced by anti-PD-1 and anti-CTLA-4 mAbs4. Suppression of metastasis by mAb 3.3 is dependent on NK cells, CD226 (DNAM-1), and IFN-γ4. Additionally, mAb 3.3 loses its antimetastatic function in CD155- and IL-12p35-deficient mice3. Antigen Distribution CD96 (aka Tactile; T cell-activated increased late expression) is mainly expressed by cells of hematopoietic origin, in particular T cells and NK cells. Ligand/Receptor CD155, nectin 1 NCBI Gene Bank ID Research Area Immunology . Inhibitory Molecules Leinco Antibody AdvisorPowered by AI: AI is experimental and still learning how to provide the best assistance. It may occasionally generate incorrect or incomplete responses. Please do not rely solely on its recommendations when making purchasing decisions or designing experiments. Clone 3.3 is a monoclonal antibody targeting mouse CD96, and its most common in vivo applications in mice include functional studies of immune modulation, particularly focusing on natural killer (NK) cells and T cells. Essential applications include:
Biological context:
Summary Table: Common In Vivo Applications of Clone 3.3
All sources agree on the main experimental uses but may differ on model specifics; suppliers and research summaries are most authoritative for antibody applications. Commonly used antibodies or proteins studied alongside "3.3"—assuming you are referring to 14-3-3 proteins (based on usage in molecular and cell biology literature)—include targets that are known 14-3-3 binding partners, regulatory kinases, or signaling intermediates. Key co-analyzed proteins/antibodies with 14-3-3 include:
Experimental methods often involve:
Other antibodies/proteins sometimes included:
Alternative 3.3 usage: If you meant antibody isotype IgG3.3 or a different target, please specify, as these are not as universally standardized and co-targets would depend on context. Summary Table: Proteins/Antibodies Commonly Used with 14-3-3 in Literature
If your context is different (e.g., a specific antibody clone "3.3"), please clarify, but most published data on "3.3" refers to the 14-3-3 protein family. No search result directly addresses "clone 3.3" citations in the context of code, biology, medicine, or any specific scientific field. The last three search results mention the word "clone," but none provide information about "clone 3.3," nor do they summarize findings from citations of such a clone in the literature. Your query could refer to a specific software tool, cell line, protein, gene, or another scientific entity—but without clarification or relevant results, it is not possible to summarize key findings from "clone 3.3" citations in the scientific literature based on the provided sources. If you have a specific scientific context or more details about "clone 3.3," please clarify so I can give a more targeted and accurate answer. Dosing regimens for clone 3.3 (an anti-mouse CD96 monoclonal antibody) vary depending on the mouse model used, experimental goals, and desired immunological outcomes. The specific dose, frequency, and route of administration may be adjusted for differences in mouse strain, disease model, or the intended effect such as cell depletion versus immunomodulation.
Key factors influencing dosing across mouse models:
Summary Table: Typical Dosing Regimen Properties for Clone 3.3
Exact clone 3.3 regimens should be validated for each new experimental setting, taking into account mouse genetics, disease burden, and desired immune impact. For additional details, refer to peer-reviewed antibody dosing guides and product-specific recommendations. References & Citations1. Georgiev H, Ravens I, Papadogianni G, et al. Front Immunol. 9:1072. 2018.
2. Chan CJ, Martinet L, Gilfillan S, et al. Nat Immunol. 15(5):431-438. 2014. 3. Roman Aguilera A, Lutzky VP, Mittal D, et al. Oncoimmunology. 7(5):e1424677. 2018. 4. Blake SJ, Stannard K, Liu J, et al. Cancer Discov. 6(4):446-459. 2016. Technical ProtocolsCertificate of Analysis |
Related Products
Formats Available
